Paion may try new sedative

Aachen (Germany) - The biopharmaceutical company Paion AG has received
approval from the U.S. Food and Drug Administration (FDA) approval for
inclusion of clinical trials on humans for the sedative CNS 7056. At
the same time, the IND (Investigational New Drug) effectively, the
company said on Wednesday.

By the end of the year should a phase I study in the U.S. are
carried out and completed, Paion. Following a phase II study is
planned with patients who undergo a medical procedure like a
colonoscopy while on concomitant sedatives. Paion acquired CNS 7056
under the recently completed acquisition of CeNeS Pharmaceuticals.